{"id":"acei-omission","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This is not a pharmaceutical agent but rather a clinical decision or study design element examining outcomes when ACE inhibitors are omitted from treatment regimens. It is used in comparative effectiveness research to evaluate the impact of ACE inhibitor use versus non-use in patient populations, particularly those with cardiovascular or renal conditions.","oneSentence":"ACEI omission refers to the clinical practice of withholding or not prescribing ACE inhibitors, typically studied as a comparative intervention rather than a drug itself.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:26:04.934Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Comparative effectiveness research in cardiovascular and renal disease management"}]},"trialDetails":[{"nctId":"NCT01669434","phase":"PHASE4","title":"Chronic Angiotensin Converting Enzyme Inhibitors in Intermediate Risk Surgery","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2015-06-01","conditions":"Hypotension on Induction","enrollment":291}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["quinapril","Accupril","perindopril","Aceon","ramipril"],"phase":"marketed","status":"active","brandName":"ACEI omission","genericName":"ACEI omission","companyName":"University of Nebraska","companyId":"university-of-nebraska","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ACEI omission refers to the clinical practice of withholding ACE inhibitors, typically studied as a comparative intervention rather than a drug product itself. Used for Comparative intervention in clinical trials (not a marketed drug product).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}